Entrada Therapeutics, Inc.
TRDA- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001689375
In the last 90 days, Entrada Therapeutics, Inc. insiders filed 0 open-market purchases and 7 sales; 128 institutions reported holding it in 13F filings for Q2 2026, worth $214.4M in total; no superinvestor holds it.
Q1 2025 vs. Q4 2024
How the institutions holding Entrada Therapeutics, Inc. changed between Q4 2024 and Q1 2025.
All holders in Q1 2025All holders in Q4 2024
| Measure | Q4 2024 | Of which not filed for Q1 2025 | Q1 2025 | Change |
|---|---|---|---|---|
| Holders | 102 | 1 | 110 | +9 |
| Shares | 30.6M | 87.5K | 30.2M | −307.7K (−1.0%) |
| Value | $529.8M | $1.51M | $274.5M | −$253.7M (−48.0%) |
1 institution that held it in Q4 2024 haven't filed for Q1 2025 yet. Not filing isn't selling, so the changes leave them out.
New holders (20)
Institutions that held Entrada Therapeutics, Inc. at the end of Q1 2025 but not at the end of Q4 2024.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Nuveen, LLC | 67,016 | $605.8K | 0.00% |
| Qube Research & Technologies Ltd | 24,993 | $225.9K | 0.00% |
| Virginia Retirement Systems Et Al | 24,800 | $224.2K | 0.00% |
| Intech Investment Management LLC | 15,305 | $138.4K | 0.00% |
| Creative Planning | 14,443 | $130.6K | 0.00% |
| Harbor Capital Advisors, Inc. | 13,403 | $121.0K | 0.01% |
| Trexquant Investment LP | 11,143 | $100.7K | 0.00% |
| Virtus Investment Advisers, Inc. | 9,065 | $81.9K | 0.02% |
| Aquatic Capital Management LLC | 1,787 | $16.2K | 0.00% |
| Zurcher Kantonalbank (Zurich Cantonalbank) | 746 | $6.74K | 0.00% |
| Covestor Ltd | 198 | $2.00K | 0.00% |
| Larson Financial Group LLC | 131 | $1.18K | 0.00% |
| Daiwa Securities Group Inc. | 150 | $1.00K | 0.00% |
| CoreCap Advisors, LLC | 48 | $434 | 0.00% |
| Hughes Financial Services, LLC | 49 | $429 | 0.00% |
| Parkside Financial Bank & Trust | 40 | $362 | 0.00% |
| Allworth Financial LP | 36 | $323 | 0.00% |
| Coldstream Capital Management Inc | 33 | $298 | 0.00% |
| Rothschild Investment LLC | 20 | $181 | 0.00% |
| SBI Securities Co., Ltd. | 1 | $9 | 0.00% |
Sold out (11)
Institutions that held Entrada Therapeutics, Inc. at the end of Q4 2024 and filed for Q1 2025 without it.
| Institution | Shares, Q4 2024 | Value, Q4 2024 |
|---|---|---|
| BayBridge Capital Group, LLC | 28,563 | $493.9K |
| ExodusPoint Capital Management, LP | 16,453 | $284.0K |
| SG Americas Securities, LLC | 14,036 | $243.0K |
| Verition Fund Management LLC | 14,030 | $242.6K |
| PDT Partners, LLC | 12,538 | $216.8K |
| Millennium Management LLC | 12,527 | $216.6K |
| Virtus ETF Advisers LLC | 3,924 | $67.8K |
| Advisor Group Holdings, Inc. | 407 | $7.04K |
| True Wealth Design, LLC | 93 | $1.61K |
| Parallel Advisors, LLC | 16 | $277 |
| EverSource Wealth Advisors, LLC | 14 | $242 |
Not filed for Q1 2025 yet (1)
Institutions that held Entrada Therapeutics, Inc. at the end of Q4 2024 and haven't filed a 13F for Q1 2025. Not filing isn't selling, so they aren't counted as sold out.
| Institution | Shares, Q4 2024 | Value, Q4 2024 |
|---|---|---|
| Nuveen Asset Management, LLC | 87,506 | $1.51M |